Study on the mechanism of Pitavastatin treatment for hepatocellular carcinoma based on Network pharmacology
OBJECTIVE To validate the efficacy of Pitavastatin in treating hepatocellular carcinoma and its molecular mechanism through Network pharmacology,molecular docking,and experiment on cells in vitro.METHODS Targets of Pitavastatin were predicted using PharmMapper.The potential targets of hepatocellular carcinoma were obtained from GeneCards,OMIM,and DisGeNet databases.The STRING database was used to obtain protein-protein interaction networks(PPI)of intersecting targets between Pitavastatin and hepatocellular carcinoma,and Cytoscape was used to obtain key targets from PPI.The affinity between Pitavastatin and the key targets was assessed using molecular docking.Finally,the effect of Pitavastatin on hepatocellular carcinoma was verified in HepG2 cells in vitro.RESULTS A total of 289 Pitavastatin targets,609 hepatocellular carcinoma targets,and 37 intersecting targets were screened.Three key targets including EGFR,ALB,and HSP90AA1 were identified by PPI.Pitavastatin had a strong affinity with the three key targets.40 μmol·L-1 Pitavastatin treatment for 24 h could inhibit the growth of HepG2 cells.CONCLUSION Pitavastatin has certain anti-hepatocellular carcinoma effects,and the mechanism may be related to EGFR,ALB,and HSP90AA1.
万方数据
维普
